Latest news with #RXRX
Yahoo
6 days ago
- Business
- Yahoo
Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.27, marking a +1.15% move from the previous day. The stock's performance was ahead of the S&P 500's daily gain of 0.83%. At the same time, the Dow added 0.77%, and the tech-heavy Nasdaq gained 1.02%. The biotechnology company's shares have seen an increase of 6.11% over the last month, surpassing the Medical sector's gain of 2.2% and the S&P 500's gain of 4.99%. The upcoming earnings release of Recursion Pharmaceuticals will be of great interest to investors. On that day, Recursion Pharmaceuticals is projected to report earnings of -$0.34 per share, which would represent year-over-year growth of 15%. Meanwhile, our latest consensus estimate is calling for revenue of $15.58 million, up 8.02% from the prior-year quarter. For the annual period, the Zacks Consensus Estimates anticipate earnings of -$1.34 per share and a revenue of $74.95 million, signifying shifts of +20.71% and +27.38%, respectively, from the last year. Investors should also take note of any recent adjustments to analyst estimates for Recursion Pharmaceuticals. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.19% higher. Recursion Pharmaceuticals is currently a Zacks Rank #3 (Hold). The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 84, finds itself in the top 35% echelons of all 250+ industries. The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Recursion Pharmaceuticals, Inc. (RXRX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
29-06-2025
- Business
- Yahoo
Why This Wildcard Stock Could Be a Future Star
The biotech industry offers numerous opportunities for investors who are willing to wait for the underlying business to reach its full potential. One such rising star is Recursion Pharmaceuticals (RXRX), which uses artificial intelligence (AI), robotic biology, and massive phenotypic screening to automate and scale drug discovery. Instead of relying on traditional hypothesis-driven R&D, Recursion created a discovery platform, which is a scalable, AI-driven discovery engine with pipeline-agnostic capabilities. Analysts: AMD Stock Will 'Close the Gap' With Nvidia by 2026. Should You Buy AMD Stock Here? The Saturday Spread: Data-Driven Trades That Cut Through the Noise (GILD, MCD, DJT) Why This Wildcard Stock Could Be a Future Star Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. This philosophy sets Recursion apart in a crowded biotech market. Furthermore, Nvidia's (NVDA) support catalyzes the company's expansion. In its most recent 13F filing, Nvidia disclosed a $40.7 million investment in the company. While Recursion stock is down 23.5% year-to-date, Wall Street expects the stock to climb higher. Recursion has built a data- and compute-intensive pipeline with near-term clinical events, resulting in a one-of-a-kind platform that combines AI, biology, and chemistry. Its diverse business model is capable of producing both pipeline-driven value and platform revenues. In May 2024, Recursion completed BioHive 2, a custom Nvidia DGX supercomputer. The performance quadrupled compared to the previous system (BioHive 1), allowing deep learning models to run on biological data gateways. Their computing power, combined with years of phenotypic data, creates a strong foundation. It powers two major value engines: internal drug pipeline advancement and platform commercial tools like licensing models, data partnerships, and pharmaceutical collaborations. Furthermore, Recursion's all-stock acquisition of UK-based Exscientia in late 2024 was a strategic win. Following its integration with Exscientia, more than five internally developed programs are now underway, each powered by Recursion OS 2.0. In the first quarter, Recursion reported revenue of $15 million, marking a 7% increase from the prior-year quarter, owing primarily to collaboration agreements. However, as a clinical-stage biotech, the company remains unprofitable. The net loss for the quarter totaled $203 million. The company ended the quarter with $509 million in cash, cash equivalents, and restricted cash balances. Furthermore, to improve financial sustainability, Recursion has reduced its projected fiscal 2025 cash burn to less than $450 million, from $600 million in 2024. It accomplished this through contract optimization, integration of high- and low-cost operations, and automation-driven efficiency, all without jeopardizing R&D advancement. The company remains well-capitalized, with a runway that extends through mid-2027. Additionally, strategic alliances with Sanofi (SNY), Roche (RHHBY), and Genentech have yielded over $450 million in non-dilutive capital. The company has no immediate plans to raise capital. Recently, Morgan Stanley kept its 'Hold' rating on the stock while lowering the price target to $5 from $8, citing the company's 'recent pipeline prioritizations, cost reductions, 20% workforce reduction, and updated cash burn guidance.' On Wall Street, analysts rate it an overall 'Hold.' Of the eight analysts covering the stock, one rates it a 'Strong Buy,' one a 'Moderate Buy,' and six as a 'Hold.' Its average target price of $6.67 indicates roughly 30% upside potential. Furthermore, its high target price of $10 implies a potential 94% gain over the next 12 months. While Recursion may have slipped under the radar when compared to biotech giants, its technology-centric model, progressive pipeline diversification, strong internal assets, significant partnership backing, and strategic capital management position it as a future star. However, it remains a high-risk, high-reward investment opportunity for aggressive investors willing to invest in the intersection of biotech and AI. On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-06-2025
- Business
- Yahoo
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $5.03, moving -6.85% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 0.52%. Meanwhile, the Dow gained 1%, and the Nasdaq, a tech-heavy index, added 0.52%. Shares of the biotechnology company have appreciated by 21.35% over the course of the past month, outperforming the Medical sector's gain of 3.5%, and the S&P 500's gain of 5.95%. Analysts and investors alike will be keeping a close eye on the performance of Recursion Pharmaceuticals in its upcoming earnings disclosure. The company is expected to report EPS of -$0.34, up 15% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $15.58 million, up 8.02% from the year-ago period. For the full year, the Zacks Consensus Estimates project earnings of -$1.34 per share and a revenue of $74.95 million, demonstrating changes of +20.71% and +27.38%, respectively, from the preceding year. Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Recursion Pharmaceuticals. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system. The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.19% upward. Right now, Recursion Pharmaceuticals possesses a Zacks Rank of #3 (Hold). The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 83, finds itself in the top 34% echelons of all 250+ industries. The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Recursion Pharmaceuticals, Inc. (RXRX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25-06-2025
- Business
- Yahoo
Morgan Stanley Trims Recursion (RXRX) Price Target, Maintains Equal Weight Rating
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of 10 AI stocks that will skyrocket. Morgan Stanley has lowered its price target on Recursion Pharmaceuticals (NASDAQ:RXRX) to $5 from $8, while maintaining an Equal Weight rating on the stock. The revision comes in response to the company's recent strategic updates, including a restructured pipeline, workforce reduction, and revised financial guidance. In a note to investors, the firm cited Recursion's recent decision to prioritize core programs and streamline operations, including a 20% reduction in headcount, as key drivers for the model revision. The company also issued updated guidance on cash burn, signaling tighter capital discipline as it focuses on long-term sustainability. A pharmacist in a hospital pharmacy stands next to a row of various drug containers. Morgan Stanley noted that while the moves could support operational focus and extend cash runway, they also reflect the challenges of advancing a broad pipeline under current market conditions. The firm views the restructuring as a necessary, though measured, step to align resources with the most promising opportunities in the portfolio. Despite the reduced target, Morgan Stanley's Equal Weight rating suggests a neutral stance, with the belief that both upside and downside risks are now more balanced given the new strategy and cost structure. Recursion Pharmaceuticals, Inc. (RXRX) is recognized for its advanced use of computational methods and machine learning to accelerate drug discovery. The firm combines biology, chemistry, and automation with data-driven approaches to identify potential treatments faster and more efficiently than traditional methods. While we acknowledge the potential of RXRX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than RXRX and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 10 Best Small Cap Tech Stocks With Biggest Upside Potential and 7 Most Popular AI Penny Stocks Under $5 To Avoid. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-06-2025
- Business
- Yahoo
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors
Recursion Pharmaceuticals (RXRX) ended the recent trading session at $5.03, demonstrating a -1.57% change from the preceding day's closing price. This move lagged the S&P 500's daily loss of 0.22%. Meanwhile, the Dow gained 0.08%, and the Nasdaq, a tech-heavy index, lost 0.51%. Coming into today, shares of the biotechnology company had gained 23.28% in the past month. In that same time, the Medical sector gained 0%, while the S&P 500 gained 0.45%. Market participants will be closely following the financial results of Recursion Pharmaceuticals in its upcoming release. In that report, analysts expect Recursion Pharmaceuticals to post earnings of -$0.34 per share. This would mark year-over-year growth of 15%. In the meantime, our current consensus estimate forecasts the revenue to be $15.58 million, indicating a 8.02% growth compared to the corresponding quarter of the prior year. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$1.34 per share and a revenue of $74.95 million, representing changes of +20.71% and +27.38%, respectively, from the prior year. It's also important for investors to be aware of any recent modifications to analyst estimates for Recursion Pharmaceuticals. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.19% higher. Recursion Pharmaceuticals is currently a Zacks Rank #3 (Hold). The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 87, placing it within the top 36% of over 250 industries. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Recursion Pharmaceuticals, Inc. (RXRX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
